Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

The Effect of taVNS and Upper GI Motility

2 de junio de 2026 actualizado por: Daniel Keszthelyi

The Effect of Non-invasive Transauricular Vagus Nerve Stimulation on Upper Gastrointestinal Motility in Healthy Individuals

This single-center randomized controlled cross-over trial aims to investigate the effect of transcutaneous auricular vagus nerve stimulation on upper gastrointestinal motility in healthy individuals.

The primary aim of this study is to assess the impact of tVNS on gut motor function, with regards to its potential to induce phase III contractions in the upper GI tract.

Secondary objectives include:

  • To study the effect of tVNS on other parameters characterizing upper GI motility such as the number of duodenal phase III contractions, gastric and duodenal phase MMCs, amplitude of antral contractions and motility index
  • To study the effect of tVNS on plasma levels of motilin and PP
  • To evaluate the effect of tVNS on parameters related to autonomic outflow, using a Shimmer3 GSR Sensor for heart rate variability and skin conductance.
  • To compare the results of the measurements of antroduodenal manometry with measurements of Gastric Alimetry

Participants will undergo tVNS (applied to the cymba conchae of the left ear) alternating with sham stimulation (using a non-conducting electrode) in a blinded, pre-randomized fashion, using two 4-hour blocks during an 8-hour fasted antroduodenal manometry recording period. Optionally, participants may simultaneously also undergo body surface gastric mapping using the Gastric Alimetry system.

Descripción general del estudio

Descripción detallada

Visit 1 (screening visit) Following written informed consent, the medical history of each subject will be checked during a structured interview. A pregnancy will be excluded by a urine test (due to the use or fluoroscopy during insertion of the manometry catheter) and a 12-lead ECG will be performed at the end of the screening visit. The rationale for this is to ensure no evidence of cardiac conduction disorders and an additional safety step to ensure no cardiac dysrhythmic affect with tVNS use. All information obtained during the screening visit will be recorded in using an electronic CRF provided by Castor EDC, provided by the Clinical Trial Centre Maastricht (CTCM).

Visit 2 (test day) Participants will arrive after an overnight fast at the GI physiology unit of the Maastricht University Medical Center, where a trained and experienced nurse will insert an antroduodenal manometry catheter through the nose into the duodenum under fluoroscopy control and supervision of a gastroenterologist (as per routine clinical procedure). Using this catheter, stomach and duodenum motility patterns will be recorded for 8 hours. After the manometry is inserted, the tVNS device will be connected with an electrode which delivers stimulation transcutaneous in the outer ear. Participants will receive two types of stimulation (i.e. tVNS vs sham) in 2 blocks of 4 hours during the 8-hour registration period. The order of stimulation applied is randomized. Gastric phase III contractions generally occur every 90 minutes, so the 4-hour period is considered sufficient to detect two phase III contractions considered sufficient to detect the two phase III contractions.(10)

An iv catheter will be inserted to draw blood during the 8-hour registration period. Blood samples, each witch a maximum volume of 10 mL, will be taken every 30 minutes to measure motilin and PP as surrogate markers of vagal efferent influence on GI motor function. In addition, autonomic parameters will be registered during the entire test period, using a Shimmer3 GSR sensor. After the 8-hour test period, the manometry catheter, the electrodes of the tVNS device and the iv cannula are removed.

Additionally, participants may opt to take part in a body surface gastric mapping assessment. This non-invasive, electrophysiological measurement is performed using the Gastric Alimetry system, which involves placing a large adhesive patch with multiple electrodes on the upper abdomen. The system records gastric myoelectrical activity over time, providing insight into gastric motility patterns. The measurement is conducted concurrently with the manometry registration period.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

12

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Limburg
      • Maastricht, Limburg, Países Bajos, 6229ER
        • Reclutamiento
        • Maastricht University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Healthy participants (defined as those without a pre-existing medical comorbidity, including those without a history of cardiac arrhythmia).
  • Age between 18 and 55 years.
  • Ability to understand and speak the Dutch language.

Exclusion Criteria:

  • Pregnancy or lactation.
  • Use of any substances (such as medication or recreational drugs) influencing gastrointestinal motility
  • Not meeting the inclusion criteria above.
  • Students and employees of Maastricht University are not precluded from participation, unless they have a direct personal, professional of hierarchical position with regards to any of the study team members or their department.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Transcutaneous Auricular Vagal Nerve Stimulation
TaVNS
taVNS will be provided during a 4-hour block of the 8-hour fasted antroduodenal manometry recording period.
Comparador de placebos: Sham stimulation
Sham stimulation with a non-conducting electrode
Sham stimulation will be provided during a 4-hour block of the 8-hour fasted antroduodenal manometry recording period.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
A clinically meaningful increase in phase III contractions
Periodo de tiempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
A clinically meaningful increase in the number of phase III contractions of antral origin in the fasted period during the tVNS stimulation compared to the sham stimulation.
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
A clinically relevant increase in other upper GI motility parameters
Periodo de tiempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
A clinically relevant increase in other parameters characterizing upper GI motility such as the number of duodenal phase III contractions, gastric and duodenal phase MMCs, amplitude of antral contractions and motility index
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Concentration of plasma motilin and pancreatic polypeptide
Periodo de tiempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Changes in plasma motilin and pancreatic polypeptide following taVNS vs. sham stimulation
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Autonomic response: heart rate variability
Periodo de tiempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Changes in heart rate variability measured continuously using a Shimmer3 GSR sensor
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Electrodermal response: skin conductance
Periodo de tiempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Changes in skin conductance following taVNS vs sham stimulation, assessed continuously using a Shimmer3 GSR sensor.
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Agreement between gastric motility measurements obtained by antroduodenal manometry and Gastric Alimetry
Periodo de tiempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Agreement between antroduodenal manometry and Gastric Alimetry measurements obtained simultaneously.
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Daniel Keszthelyi, MD, PhD, Maastricht University Medical Center

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

25 de febrero de 2025

Finalización primaria (Estimado)

1 de junio de 2026

Finalización del estudio (Estimado)

1 de junio de 2026

Fechas de registro del estudio

Enviado por primera vez

26 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

2 de junio de 2026

Publicado por primera vez (Actual)

8 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

8 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de junio de 2026

Última verificación

1 de junio de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir